In conclusion, our study divided HNSCC into two clusters based on IGF2BP2 and YTHDF1, which provided a simple and feasible tool to identify HNSCC with different immune profiles and helped estimate sensitivity to ICIs-based immunotherapy. The gene discussed is IGF2BP2; the disease is head and neck squamous cell carcinoma.